L01EA01 • imatinib • Antineoplastic and immunomodulating agents | Protein kinase inhibitors | BCR-ABL tyrosine kinase inhibitors
Imatinib is a tyrosine kinase inhibitor used for the treatment of chronic myeloid leukemia (CML) and other cancers, such as gastrointestinal stromal tumors (GIST). It works by blocking the activity of abnormal proteins that drive cancer cell growth.
The medication is taken orally, usually once daily, as directed by a doctor. It is important to follow the recommended dose to maximize treatment effectiveness.
Side effects may include nausea, vomiting, fluid retention, muscle pain, or fatigue. In rare cases, severe allergic reactions or liver failure may occur.
Imatinib is not recommended for patients with hypersensitivity to this medication or severe liver impairment.
Substance: imatinib
Date of last drug list: 01-08-2018
Commercial code: W64412004
Concentration: 400mg
Pharmaceutical form: dispersible tablets
Quantity: 90
Product type: generic
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).